Yposkesi signs with Servier to manufacture allogenic CAR-T

By Maggie Lynch

- Last updated on GMT

(Image: Getty/Juan Gaertner/Science photo library)
(Image: Getty/Juan Gaertner/Science photo library)

Related tags Manufacturing CAR-T T cell T cell receptor T cells Viral vector hematological

Servier to work with Yposeski for the production of lentiviral vectors, as the former works to develop allogenic CAR-T cell technology for hematological therapies.

Yposkesi, a gene therapy contract development and manufacturing organization (CDMO), will provide good manufacturing practice (GMP) production of lentiviral vectors to Sevier as the company continues to develop allogenic chimeric antigen receptor (CAR) T-cell technology for hematological malignancies.

According to Servier, cell-based gene therapies that have been obtained with autologous CAR-engineered products have demonstrated positive results in treating hematological malignancies.

Allogenic CAR-T therapies, which will be developed per this agreement, hold the potential to be manufactured in large batches, creating off-the-shelf treatments for a larger number of patients, as opposed to autologous treatments which are created individually from patient’s cells.

Pierre Venesque, EVP of industry at Servier, said in a statement, “Allogenic CAR-T cell therapy is a promising new technology with an amazing potential to treat cancer patients.”

Per the agreement, Servier will have access to Yposkesi’s technology for lentiviral vector manufacturing, which has been used in several clinical trial programs in the EU and US, as well as analytical development, quality assessment resources and capacity.

Servier said it will be focusing 50% of its R&D budget on oncology over the next two years, with a focus on therapies aiming to restore programmed cell death in cancer cells. The company currently has five treatments on the market and is developing 12 therapeutic options.

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Follow us


View more